

1st MCCT

11-13 February 2015

Maastricht, The Netherlands

Venous thromboembolism (VTE) is a potentially fatal disorder that occurs without apparent provocation (primary, or idiopathic) or after exposure to risk factors, such as surgery. In general much is known about the causes and consequences of VTE. In spite of that, many questions remain to be answered. Regarding the mechanisms of VTE the role of inflammation and the contribution of platelets and neutrophils to thrombogenesis is largely unknown. In the diagnosis of VTE there is some development in distinguishing old and new thrombi, but this is still challenging and clinically relevant topic. In the management of the patient with VTE, there is a spectrum of anticoagulants becoming available, but which one is the ideal agent for a given patient. What are avoidable side effects? Are "pleiotropic" drugs like statins useful in preventing recurrent VTE or not? How invasive should we become in the therapy for the patient with ileo-femoral thrombosis, or with pulmonary embolism? How safe are these procedures and how do we deal with the "vulnerable" patient with VTE?

These and many other questions not only merit our attention, but demand an active "think tank" of those active in the field of venous thromboembolism. In this first edition of the Maastricht Consensus Conference on Thrombosis we intend together with a distinguished international faculty and in close interaction with the audience, to develop a roadmap for research that needs to be done!

Programme 11 February 2015

- 07.00 - 08.30 Registration participants | Registrion desk MECC - Lobby
- 08.30 - 10.00 Plenary session (Topic 1) | [Room 0.4/0.5](#)
Pathogenesis of VTE and PTS
Chairs: Pieter Reitsma, Paola van der Meijden
- 08.30 Opening - Guy Peeters
- 08.30 - 08.45 Platelets as inflammatory mediators - Yukio Ozaki
- 08.45 - 09.00 Endothelium, leukocytes, interactions -† Wolfram Ruf
- 09.00 - 09.15 Red cells - Bas de Laat
- 09.15 - 09.30 Coagulation and Fibrinolysis †- Nicola Mutch
- 09.30 - 09.45 Cells, hemodynamics and thrombosis - Scott Diamond
- 09.45 - 10.00 Microparticles -† Rienk Nieuwland
- 10.00 - 10.30 Coffee break | Exhibition area - Lobby
- 10.30 - 12.00 6 workshops
- Yukio Ozaki - Room 0.1
Wolfram Ruf - Room 0.2
Bas de Laat - Room 0.3
Nicola Mutch - Room 0.6/0.7
Scott Diamond - Room 0.8
Rienk Nieuwland - Room 0.9
- 12.00 - 13.00 Consensus discussion | [Room 0.4/0.5](#)
- 13.00 - 14.00 Lunch | Exhibition area - Lobby
- 14.00 - 15.30 Plenary session (Topic 2) | [Room 0.4/0.5](#)
Epidemiology, biomarkers, imaging of (recurrent) VTE and PTS
Chairs: Trevor Baglin, Henri Spronk
- 14.00 - 14.15 Epidemiology - Suzanne Cannegieter
- 14.15 - 14.30 Genetics - Pierre Morange
- 14.30 - 14.45 Thrombin Generation †- Tilman Hackeng
- 14.45 - 15.00 Imaging of clot and vessel wall †- Menno Huisman
- 15.00 - 15.15 Biomarkers of Venous Thrombosis -† Nigel Mackman
- 15.15 - 15.30 Prediction of recurrent VTE and PTS †- Trevor Baglin
- 15.30 - 16.00 Coffee break | Exhibition area - Lobby
- 16.00 - 17.30 6 workshops
- Suzanne Cannegieter - Room 0.1
Pierre Morange - Room 0.2
Tilman Hackeng - Room 0.3
Menno Huisman - Room 0.6/0.7
Nigel Mackman - Room 0.8
Trevor Baglin - Room 0.9
- 17.30 - 18.30 Consensus discussion | [Room 0.4/0.5](#)
- 19.30 - 20.30 Welcome Reception | City Hall Maastricht

Programme 12 February 2015

- 08.30 - 10.00 Plenary session (Topic 3) | [Room 0.4/0.5](#)
Management of (recurrent) VTE and PTS, non-invasive
Chairs: Harry Buller, Arina ten Cate - Hoek
- 08.30 - 08.45 Role of statins - Harry Buller
- 08.45 - 09.00 New Oral Anticoagulants for VTE Treatment; which patients, which drug and which dose? - Jeff Weitz
- 09.00 - 09.15 Direct coagulation inhibitors - David Gailani
- 09.15 - 09.30 Platelet inhibitors - Karina Meijer
- 09.30 - 09.45 Contact activation inhibitors - Helen Philippou
- 09.45 - 10.00 Management of the patient with PTS - Arina ten Cate - Hoek
- 10.00 - 10.30 Coffee break | Exhibition area - Lobby
- 10.30 - 12.00 6 workshops
- Harry Buller - Room 0.1
Jeff Weitz - Room 0.2
David Gailani - Room 0.3
Karina Meijer - Room 0.6/0.7
Helen Philippou - Room 0.8
Arina ten Cate - Hoek - Room 0.9
- 12.00 - 13.00 Consensus discussion | [Room 0.4/0.5](#)
- 13.00 - 14.00 Lunch
- 14.00 - 15.30 Plenary session (Topic 4) | [Room 0.4/0.5](#)
Management (recurrent) VTE and PTS, invasive
Chairs: Tony Comerota, Cees Wittens
- 14.00 - 14.15 Late effects of clot removal - Per Morten Sandset
- 14.15 - 14.30 Clot removal in PE - Stavros Konstantinides
- 14.30 - 14.45 Stenting - Rick de Graaf
- 14.45 - 15.00 AV - Fistula - Tony Comerota
- 15.00 - 15.15 The Intersection of Thrombosis and Inflammation in Venous Thrombosis - Thomas Wakefield
- 15.15 - 15.30 Diagnostics in PTS - Carsten Arnoldussen
- 15.30 - 16.00 Coffee break | Exhibition area - Lobby
- 16.00 - 17.30 6 workshops
- Per Morten Sandset - Room 0.1
Stavros Konstantinides - Room 0.2
Rick de Graaf - Room 0.3
Tony Comerota - Room 0.6/0.7
Thomas Wakefield - Room 0.8
Carsten Arnoldussen - Room 0.9
- 17.30 - 18.30 Consensus discussion | [Room 0.4/0.5](#)
- 19.30 Social Event | Thiessen Wijnkoopers

Programme 13 February 2015

- 08.30 - 10.00 Plenary session (Topic 5) | [Room 0.4/0.5](#)
How to safely manage antithrombotic therapy in the vulnerable patient
Chairs: Hugo ten Cate, Yvonne Henskens
- 08.30 - 08.35 Introduction - Hans Fiolet
- 08.35 - 09.00 Prevention of thrombosis in pregnant women - Saskia Middeldorp
- 09.05 - 09.30 Thrombosis in patients with cancer - Anna Falanga
- 09.35 - 10.00 Thrombosis prevention in (all) medical patients? - Martin Prins
- 10.05 - 10.30 How to support thrombosis prevention? Lessons from the digital era - Pieter Kubben
- 10.30 - 11.00 Coffee break | Exhibition area - Lobby
- 11.00 - 12.30 Plenary session: Topic 1 & 2 | [Room 0.4/0.5](#)
- 12.30 - 13.30 Lunch | Exhibition area - Lobby
- 13.30 - 15.00 Plenary session: Topic 3 & 4 | [Room 0.4/0.5](#)

Speakers



Carsten Arnoldussen

Carsten W.K.P. Arnoldussen MD. VieCuri Medical Centre & Maastricht University Medical Centre, Maastricht University, The Netherlands.

Dr. Arnoldussen is an interventional-radiologist based at the VieCuri Medical Centre in Venlo and Maastricht University Medical Centre in Maastricht. His clinical focus is on minimally invasive treatment options for vascular disease.

Dr. Arnoldussen's research at the Maastricht University Medical Centre is centered around visualisation of vascular disease to identify patients eligible for (minimally) invasive treatment. The goal is to prevent, diagnose, treat and improve outcomes of patients with acute and chronic venous disease. The main focus is non-invasive, diagnostic assessment of deep vein thrombosis and chronic venous obstruction.



Trevor Baglin

Trevor Baglin is Consultant Haematologist to Cambridge University Hospitals. His main expertise is in thrombosis and haemostasis and in particular antithrombotic therapy, venous thromboembolism and thrombophilia. His clinical research programme on venous thromboembolism has contributed to personalised patient risk profiling and informed guidelines. His work on molecular recognition of blood coagulation proteins has provided a framework for targeted rational drug design in the field of haemostasis and thrombosis.



Harry Buller

Academic Medical Center Amsterdam, The Netherlands

Harry Büller, MD, is professor of internal medicine, specializing in vascular medicine, at the Academic Medical Center in Amsterdam, The Netherlands.

Professor Büller earned his MD and PhD from the University of Amsterdam. After graduating, he completed his research fellowship in hemostasis and thrombosis in the Departments of Medicine and Clinical Epidemiology and Biostatistics at McMaster University in Hamilton, Ontario, Canada.



Suzanne Cannegieter

Suzanne Cannegieter trained as a medical doctor but moved to the field of Clinical Epidemiology after obtaining a MSc in Epidemiology at the London School of Hygiene and Tropical Medicine. She is a staff member at the department of Clinical Epidemiology at the Leiden University Medical Center where she focuses her research on the field of venous thrombosis, with a particular interest in its aetiology, as well as in establishing optimal prevention and therapy. A few examples of topics include the relation between air travel and venous thrombosis, the association between endocrine hormones and venous thrombosis, and risk factors for recurrent thrombosis. She is also PI of two randomised clinical trials into thrombosis prophylaxis for patients with lower leg immobilisation and knee arthroscopy.



Arina ten Cate - Hoek

Arina ten Cate, MD, PhD, Msc Epidemiology, is clinician-epidemiologist at the MUMC & Laboratory for Clinical Thrombosis and Hemostasis, CARIM and medical director of the Maastricht Anticoagulation Clinic.



Anthony Comerota

Anthony J. Comerota, MD, FACS, FACC, Director of the Jobst Vascular Institute at ProMedica Toledo Hospital, Toledo, Ohio and Adjunct Professor of Surgery at the University of Michigan, received his medical degree from Temple University School of Medicine in Philadelphia, PA, and completed his general surgery residency at Temple University Hospital and his vascular surgery fellowship at Good Samaritan Hospital, Cincinnati, OH.



Scott Diamond

Scott L. Diamond (BS 1986, Cornell University; Ph.D. 1990, Rice University) holds the Arthur E. Humphrey Chair of Chemical and Biomolecular Engineering at the University of Pennsylvania. Diamond is the founding director of the Penn Center for Molecular Discovery. Dr. Diamond

researches Cardiovascular Therapeutic Technologies in several key areas: mechanobiology, blood clot dissolving therapies and protein therapeutics, blood coagulation, drug discovery, and nonviral gene therapy. His laboratory has advanced biomedical research with more than \$23 million in research funding from the Cystic Fibrosis Foundation, American Heart Association, NIH and NSF. He has produced over 180 publications and patents. He is the recipient of the NSF National Young Investigator Award, the NIH FIRST Award, the AHA Established Investigator Award, and the AIChE Colburn Award. He is an elected fellow of the Biomedical Engineering Society.



Anna Falanga

Anna Falanga, MD, is Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. After having received her medical degree and board certification in internal medicine at the University of Naples, Dr. Falanga obtained her board certification in Hematology at the University of Verona, Italy. Subsequently, she spent three years working as a postdoctoral fellow at the Mario Negri Institute in Milan, Italy, and a further two years at the University of Colorado School of Medicine, Denver, CO, USA.

Dr. Falanga has been involved in the field of research on “Cancer & Thrombosis” for many years. For her experience in the field, she is a member of the panel of experts and a co-chair for the preparation of the Guidelines of prophylaxis and treatment of venous thromboembolism in patients with cancer, for the Italian Society of Medical Oncology, the American Society of Clinical Oncology and the European Society of Medical Oncology. In July 2009 she was awarded the BACH Investigator Award of the ISTH.

Dr Anna Falanga has authored numerous papers. She has an active role in several professional societies and is currently President-Elect of the Italian Society on Thrombosis and Hemostasis. She is also involved in the organization of numerous scientific conferences, including the co-chairmanship of seven biennial International Conference on “Thrombosis and Hemostasis Issues in Cancer” (ICTHIC), held in Bergamo, Italy.



David Gailani

David Gailani is Professor of Pathology, Microbiology and Immunology and Professor of Medicine at Vanderbilt University Medical School, Nashville, Tennessee, USA. He received his bachelor of arts from Cornell University (1980), medical degree from the University of Illinois (1984), completed a residency in medicine at the University of Iowa (1988), and did fellowship and research training in hematology at Washington University, St. Louis. Dr. Gailani’s research laboratory focuses on the biochemistry and pathophysiology of the intrinsic pathway of coagulation, with an emphasis on the roles of factor XI and factor XII in thrombosis and inflammation.



Rick de Graaf

Rick de Graaf MD, PhD studied Medicine at the University of Maastricht, The Netherlands. He obtained his PhD at the Department of Surgery and Medical Microbiology of the Maastricht University Medical Centre, The Netherlands. He received his training in Radiology at the Maastricht University Medical Centre and obtained his board license in 2010. At present he works as a staff Interventional Radiologist, with major focus on deep venous interventions and neurovascular interventions. His main research activities include the diagnosis and treatment of acute and chronic deep venous obstruction.



Tilman Hackeng

Tilman Hackeng studied (bio)chemistry at the University of Utrecht where he obtained his Masters Degree in 1988. After his military draft he finished his Ph.D. in 1993 and left for The Scripps Research Institute, La Jolla, CA, USA, where he worked in the laboratories of Professors Griffin (Mol & Exp. Medicine) and Kent (Cell Biology/Chemistry). In 1998 he was granted a position as a Research Fellow of the Royal Netherlands Academy of Arts and Sciences (KNAW) at the Department of Biochemistry (Prof Rosing) at the University Maastricht, the Netherlands. In 2002 he received a personal VIDI grant from The Netherlands Organisation for Scientific Research (NWO). Currently, he is Head of the Department of Biochemistry where he studies anticoagulant protein C/protein S/TFPI pathways and applies total chemical protein synthesis to the development of peptide/protein-based contrast agents for in vivo imaging of cardiovascular diseases. He is past president of the Netherlands Society on Thrombosis and Hemostasis and Board Member of the Cardiovascular Research Institute Maastricht (CARIM).



Menno Huisman

Professor Huisman received his medical degree and defended his PhD thesis to get a doctorate at the University of Amsterdam, the Netherlands. The Academic Medical Center in Amsterdam was host to his training in internal medicine and haematology. At present he is staff member in the department of Medicine at Leiden University Medical Center Leiden, The Netherlands. His main research activities include the diagnosis and treatment of thromboembolic disorders.



Stavros Konstantinides

Dr Konstantinides is Professor for Clinical Trials and Medical Director of the multidisciplinary Centre for Thrombosis and Haemostasis (CTH) at the University of Mainz, Germany. The CTH is dedicated to patient care and translational research and is funded by the federal German government. Dr Konstantinides is also Professor of Cardiology at the Democritus University of Thrace, Greece. He graduated from Medical School of the Aristotle University, Thessalonica, Greece. He then completed his clinical training in Cardiology and defended his thesis at the University of Freiburg Germany. He has worked as consultant cardiologist at the Universities of Freiburg and Goettingen, Germany, and as a research associate at the Department of Vascular Biology, the Scripps Research Intitute, La Jolla, CA, USA. His research focuses on basic mechanisms of thrombosis and on the risk stratification and antithrombotic management of venous thromboembolism. He has published over 170 papers in peer-reviewed journals with a cumulative impact factor of over 1,000, and more than 20 book chapters. He has designed and coordinated, as principal investigator, several national and international multicenter trials. His research is being supported by national and European peer reviewed granting agencies. Dr. Konstantinides has headed the European Society of Cardiology (ESC) task force for the 2014 update of the Guidelines on the Management of Acute Pulmonary Embolism.



Pieter Kubben

Pieter Kubben is a staff neurosurgeon who works at the Maastricht University Medical Center in The Netherlands and performed a PhD thesis on glioma surgery with intraoperative MRI.

As a hobby, he started developing software for mobile computing and clinical decision support.

Starting in 2001, he has won two international awards for his efforts in PHP & MySQL.

Since 2009 he focuses on Rich Internet Applications and developing mobile apps for iOS, Android and Windows 8.

In 2010 he released three medical iPhone apps, and became IT editor and associate editor-in-chief of the open-access journal Surgical Neurology International. One of his apps, called NeuroMind, became the #1 ranked app for neurosurgery for iPhone, iPad and Android. It has been mentioned three times in the widely cited "Top Apps" on iMedicalApps.com, and is also available for Windows 8.

Testimonials and media coverage are available [here](#).

In 2011 he gave a TEDx talk explaining his philosophy behind the apps, and his vision on clinical decision supporting systems (CDSS). Such systems are implemented in NeuroMind 2.0 which was released in April 2012.

Twice he was named one of the "Top Ten Internet-Smart Doctors in the World" by the weblog InternetMedicine.com, both for 2012 and for 2013.

Since 2014 he works as a staff neurosurgeon with a focus on functional neurosurgery (deep brain stimulation, epilepsy surgery, and brain computer interfaces). He is part-time employed at the department of medical information technology to develop new innovative approaches in eHealth and mHealth.



Bas de Laat

After successfully defending my thesis (antiphospholipid antibodies and thrombosis) in 2005 I continued working at the lab of Prof. Ph.G. de Groot (UMC Utrecht). Beta2-glycoprotein I and antiphospholipid antibodies were main subject of interest. In 2006 I changed institutes by becoming senior post-doc within the group prof. K. Mertens and head “Experimental Blood Coagulation” laboratory at Sanquin Blood Supply foundation. In 2006 I obtained a personal fellowship from the Netherlands Heart Foundation to investigate the role of beta2-glycoprotein I on platelet adhesion to Von Willebrand Factor (VWF). During my career at Sanquin Blood Supply Foundation I visited the Ruggeri Laboratories (The Scripps Research Institute, La Jolla, CA) in 2009 for one year to increase knowledge on VWF, GPIb and thrombin. The last few years VWF and thrombotic thrombocytopenic purpura have been subjects of interest. In 2011 I received an additional grant from the Netherlands Heart Foundation to investigate the interaction between VWF and fibrin with ultimate goal the characterization of thrombin generation under influence of flow. Based on the fact that thrombin generation had become the main subject of interest, I decided to change institutes and I am currently director of Synapse BV, a spin-off company from the department of Biochemistry at the Maastricht University. Recently we have developed a method to study thrombin generation in whole blood for which we obtained several grants from the Center for Translational Molecular Medicine and NWO. In addition I am associate professor at the Maastricht University, visiting scientist at the University Medical Center Utrecht, The Scripps Research Institute and Cornell University. Since 2013 I am chair of the lupus anticoagulant committee of the ISTH-SSC and reviewer for several journals including Blood, Journal of Thrombosis and Haemostasis, Lancet, New England Journal of Medicine, etc....



Nigel Mackman

In my early career at the University of Leicester (7 years) I studied bacterial pathogenesis. I cloned the hemolysin operon from pathogenic *Escherichia coli*. This operon encodes four proteins: hemolysin toxin (HlyA), a protein required for activation of the toxin (HlyC) and two proteins (HlyB and HlyD) that are required for secretion of the toxin. Interestingly, HlyB is highly homologous to the mammalian ATP-binding cassette transmembrane drug transporter P-glycoprotein. I identified a 23 amino-acid C-terminal secretion sequence in HlyA and showed that it could be used to secrete other proteins from *bacteria*. In the second phase of my career (27 years) I have studied the role of tissue factor (TF), coagulation proteases and protease activated receptors (PARs) in hemostasis, thrombosis, inflammation, ischemia-reperfusion injury, cancer, sickle cell disease, viral infection and atherosclerosis. I spent 20 years at the Scripps Research Institute before moving to the University of North Carolina at Chapel Hill. In 1989 I cloned the human TF gene. I demonstrated that the transcription factors AP-1, NF- κ B and Egr-1 are required for LPS induction of TF gene expression in human monocytic cells. We have generated several unique mice that have altered levels of TF, including low TF mice and mice with a floxed TF gene. We found that mice with reduced levels of TF exhibit spontaneous bleeding in certain tissues and this led us to propose a model of tissue specific hemostasis. We have determined that TF expression by both monocytes and non-hematopoietic cells

leads to activation of coagulation during endotoxemia. In addition, TF, coagulation proteases and PARs contribute to acute injury and remodeling following cardiac ischemia-reperfusion injury. This suggests that inhibition of these pathways may reduce cardiac remodeling and heart failure. Recently, we discovered that hyperlipidemia activation of coagulation is mediated by TF expression in monocytes and TF-positive microvesicles. Importantly, simvastatin inhibited monocyte TF expression, which may explain some of the anti-thrombotic activity of statins. We also found that tumor-derived TF-positive microvesicles enhance venous thrombosis in mouse models of pancreatic cancer, and are a novel biomarker for venous thrombosis in cancer pancreatic cancer patients. TF also activates coagulation and enhances inflammation in a mouse model of sickle cell disease. A recent exciting discovery from our lab is that the TF-thrombin-PAR-1 pathway plays a role in the innate response to viral infection by contributing to expression of the anti-viral protein interferon- β . I have been a Chartered Member of an NIH Study Section, reviewed for the American Heart Association and have been an Associate Editor for Thrombosis and Hemostasis, the Journal of Thrombosis and Hemostasis and an Arteriosclerosis, Thrombosis and Vascular Biology (ATVB). I am currently an Associate Editor for the Journal of Clinical Investigation and Senior Associate Editor for ATVB. I have served as Chair of the Hemostasis Gordon Research Conference and Chair of the ATVB council of the American Heart Association. I have also mentored 28 Postdoctoral Fellows and 4 Medical students and 1 graduate student. I have published 200 original scientific papers, 65 reviews and 21 editorials.



Karina Meijer

Karina Meijer (1970) qualified as an MD at Groningen University, where she also gained a PhD degree (2002, thesis on liver disease in patients with coagulation disorders). She trained as a haematologist in Zwolle, Groningen and Hamilton, Canada. From 2012, she is head of the division of Thrombosis and Haemostasis at the University Medical Centre Groningen. Her main clinical interests are haemophilia and venous thrombosis. Her research interests center on quality of anticoagulation and reversal strategies for antithrombotic therapy.



Saskia Middeldorp

Saskia Middeldorp is Professor of Medicine, Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.

Saskia Middeldorp, MD, qualified as a medical doctor at the University of Amsterdam in 1992. She received her training in internal medicine at the Academic Medical Center in Amsterdam and obtained her board licence in 1999 (subspecialty Vascular Medicine, 2002). Since December 2010, she is professor and co-chair of the Department of Vascular Medicine of the Academic Medical Center. She leads the residency program of vascular medicine and the clinical thrombosis and haemostasis research lines of the Department. Her present research focuses on several aspects of hereditary and acquired thrombophilia, women's issues in thrombosis and haemostasis, and the clinical evaluation of new anticoagulants.



Pierre Morange

Professor Pierre-Emmanuel Morange (MD, PhD) is the Head of the Laboratory of Haematology in the Centre Hospitalier Universitaire (CHU) Timone, Professor of Haematology in the Faculty of Medicine at the Aix-Marseille Université and Director of the Centre de Référence Régional pour l'Exploration des Pathologies Hémorragiques et Thrombotiques (CEHT) at CHU Timone, all in Marseille, France. He has special expertise in genetic epidemiology, haemostasis and thrombophilia. He has published more than 180 peer-reviewed manuscripts.



Nicola Mutch


Nicola J Mutch, BSc, PhD is Senior Lecturer & British Heart Foundation Research Fellow - Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen

Education

1993-1997 Undergraduate:- University of Aberdeen, BSc (Hons) in Molecular Biology (2i)
1997-2000 Postgraduate:- University of Aberdeen 'Local thrombin activity in thrombi and the vessel wall'

Employment

2001-2003 Postdoctoral research fellow, University of Aberdeen, UK
2004-2006 Postdoctoral research associate, University of Illinois at Urbana-Champaign, USA
2007-2010 Independent Research Fellow in cardiovascular medicine at the University of Leeds, UK
2010 – present British Heart Foundation Senior Research Fellow, University of Aberdeen



Rienk Nieuwland

Rienk Nieuwland studied Biology at the University of Utrecht (Utrecht, The Netherlands). He obtained his PhD at the Department of Haematology of the University Medical Centre Utrecht (Utrecht, the Netherlands). Since 2002, he works at the AMC (Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands), where he is Principal Investigator and Head of the Laboratory of Experimental Clinical Chemistry. His scientific interests are isolation, detection, and functional characterization of extracellular vesicles, and platelets. He chairs the Scientific Standardization Committee on Vascular Biology of the International Society on Thrombosis and Haemostasis (ISTH), has co-authored on more than 120 scientific papers and book chapters on vesicles and platelets, is member of the Editorial Board of the Journal of Extracellular Vesicles,

coordinates the European Metrology Research Project METVES (www.metves.eu), and was one of the organisers of the 3rd meeting of International Society of Extracellular Vesicles (ISEV) as well as the first combined Educational Day of ISEV and ISTH (Rotterdam, 2014).



Yukio Ozaki

Yukio Ozaki, MD, PhD

Membership and Editorial activities:

Council member, International Society of Thrombosis and Hemostasis
Chairman, Japanese Society of Thrombosis and Hemostasis
Council member, Japanese Society of Laboratory Medicine
Senior Associate Editor, Thrombosis Research
Co-Editor-in-Chief, Thrombosis Journal
Associate Editor, Journal of Thrombosis and Haemostasis
Treasurer, Asian and Pacific Society of Thrombosis and Hemostasis

Area of interests:

1. Signal transduction pathways, particularly those involving tyrosine kinases
2. Interaction between platelet surface glycoproteins and extracellular matrices
3. Developing new methods for detection of activated platelets and microparticles.
4. Exploring the biological significance of CLEC-2 on the platelet membranes in various tissues

Recent main activities in ISTH:

1. State-of-the-Art presentation, The XX Congress of the International Society on Thrombosis and Haemostasis (2005) Yukio Ozaki: Platelet GPIb-IX-V-dependent signaling
2. State-of-the-Art presentation, The XXII Congress of the International Society on Thrombosis and Haemostasis (2009) Yukio Ozaki: Novel interactions in platelet biology
3. Editor-in-Chief of the State of the Art Book, (2011 Kyoto ISTH Congress)
4. State-of-the Art presentation, The XXIII Congress of the International Society on Thrombosis and Haemostasis (2013) Yukio Ozaki: Platelet receptors activated by multimerization



Helen Philippou

Helen Philippou completed her PhD under the supervision of Prof David A Lane and obtained a permanent position with David Lane immediately upon completion of her PhD (at Imperial College, London). In total she worked with David Lane for 10 years before moving to a permanent position at the University of Leeds. At Leeds, she is applying the knowledge she has gained on mechanisms of thrombosis to the development of novel targets for anti-thrombotic agents. In addition, Dr Philippou leads the development of drug discovery programmes (small molecules or peptides) to develop novel anti-thrombotic agents with minimal risk of bleeding



Martin Prins

Professor M.H. (Martin) Prins completed his training as MD in 1983. After a period as Physician-Officer in the Royal Dutch Navy he started his training in internal medicine in 1989. He spent 2 years in Hamilton, Canada at McMaster University, where he studied clinical epidemiology and performed research in thrombosis. In 1992 he completed his internal medicine education and in 1993 he defended his thesis entitled "Clinical and methodologic studies in thrombosis". He then worked at the Amsterdam Medical Center as head of the trial unit until 2001, when he went to Maastricht University as professor of Clinical Epidemiology and chairman of the department of Epidemiology. He has coached 37 PhD students, has co-authored more than 400 scientific publications and has a Hirsch-index of 72.



Pieter Reitsma

Pieter Reitsma (PhD, Leiden, 1982) is professor of Experimental and Molecular Medicine at Leiden University. He is chair of the department of Thrombosis and Hemostasis and of the Einthoven Laboratory for Experimental Vascular Medicine, both located in the Leiden University Medical Center. His current work focuses on genetic aspects of risk factors for thrombotic disease. Pieter Reitsma is co-editor in chief of the Journal of Thrombosis and Haemostasis and in that capacity also member of the council of the International Society on Thrombosis and Haemostasis.



Wolfram Ruf

Wolfram Ruf, M.D., is Professor in the Department of Immunology and Microbial Science at The Scripps Research Institute in La Jolla, CA and holds an Alexander von Humboldt Professorship and is the Scientific Director of the Center for Thrombosis and Hemostasis at the University Medical Center in Mainz, Germany. Dr. Ruf's research over last 25 years is focused on the tissue factor (TF) initiated coagulation pathway in thrombosis, inflammation, angiogenesis and tumor biology. In addition to an interest in the structural biology, regulatory mechanisms, and cell biology of the TF initiation complex, he studies the signaling functions of coagulation proteases, co-receptors and protease activated receptors (PARs) in genetic mouse models of human diseases and develops and evaluates novel diagnostic and therapeutic approaches to target these pathways in cancer, thrombosis, and inflammatory disorders.



Per Morten Sandset

Per Morten Sandset, MD, PhD, is the Research Director of the Division of Cancer Medicine, Surgery and Transplantation at Oslo University Hospital, and Professor of Hematology/Thrombosis Research, University of Oslo. His main research activities concerns studies of tissue factor pathway inhibitor, clinical studies on treatment of venous thrombosis (including catheter-directed thrombolytic therapy) and acute ischemic stroke and on the pro-thrombotic effects of estrogen therapy, and epidemiological studies on clinical, phenotypic and genetic risk factors of pregnancy related venous thrombosis. He currently president of the Norwegian Society on Thrombosis and Haemostasis and has been responsible for the development of Norwegian guidelines.



Thomas Wakefield

Thomas W. Wakefield, MD is the Stanley Professor of Vascular Surgery; Head, Section of Vascular Surgery and Director of the Samuel and Jean Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, MI. He attended St. John's Jesuit High School and then obtained his BA degree from the University of Toledo in 1975 and is a proud graduate of the Honors Program. He received his MD degree from the Medical College of Ohio in 1978, and then moved to the University of Michigan where he began and finished general surgery and vascular surgery training. He joined the faculty of the University of Michigan, Section of Vascular Surgery in 1986. He was awarded an endowed chair in 2002, the S. Martin Lindenauer Collegiate Chair in Vascular Surgery, and become Section Head in 2004. In February, 2012 he became the Stanley Professor in Vascular Surgery and in 2014 he became a Director of the Samuel and Jean Frankel Cardiovascular Center.



Jeff Weitz

Jeffrey I. Weitz, MD, FRCP(C), FACP, FCCP, FAHA, FACC, FESC, FCAHS
Professor of Medicine & Biochemistry, McMaster University
Executive Director, Thrombosis & Atherosclerosis Research Institute,
Hamilton, Ontario, Canada

Dr. Weitz is a Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz now focuses his clinical work in the area of thrombosis.

He holds an Endowed Chair in Cardiovascular Research at McMaster University, which is funded by the Heart and Stroke Foundation of Ontario. He also holds the Canada Research Chair (Tier 1) in

Thrombosis. Dr. Weitz received the Medal in Medicine from the Royal College of Physicians and Surgeons of Canada in 1991, the Distinguished Scientist Award from the Heart and Stroke Foundation of Ontario in 1999, the Research Achievement Award from the Canadian Cardiovascular Society in 2006, the Jack Hirsh Award for Outstanding Academic Achievement from McMaster University in 2008, the Innovator Award from McMaster University in 2010, and the Special Recognition Award in Thrombosis from the American Heart Association in 2011. He is a member of the American Federation of Medical Research, the American Society for Clinical Investigation, and the Association of American Physicians, a Fellow of the American Heart Association, American and European Colleges of Cardiology, American College of Chest Physicians, and the Canadian Academy of Health Sciences. Dr. Weitz gave the Davidson Lecture at the University of Edinburgh in 2000, the Nossel Memorial Lecture at Columbia University in New York in 2003, and the Mosesson Lecture at the Blood Research Institute in Milwaukee in 2008. He directs a well-funded research laboratory that focuses on the biochemistry of blood coagulation and fibrinolysis as it applies to venous and arterial thrombosis. A former Vice-President of Research for the Heart and Stroke Foundation, member of the Board of Directors of the Heart and Stroke Foundation of Ontario, Chair of the Scientific Review Committee for the Heart and Stroke Foundation of Canada, member of the Executive Council on Thrombosis of the American Heart Foundation, and Chair of the Council on Vascular Biology for the American Society of Hematology, Dr. Weitz has published over 375 peer-reviewed papers and 50 textbook chapters.

Sponsors

The Organizing Committee of the MCCT gratefully acknowledges contributions. The sponsor/exhibitor list will be regularly updated. For further information regarding sponsorship opportunities, please send an email to the Congress Secretariat: info@mcct.eu

Partner

Maastricht UMC+



Gold Sponsors

LEO Pharma B.V.



Silver Sponsors

AngioDynamics Netherlands B.V.



Aspen Netherlands B.V.



Bayer

BTG



BTG

Covidien Vascular Therapies



COVIDIEN

Daiichi-Sankyo



Daiichi-Sankyo

Lohmann & Rauscher B.V.



medi Nederland B.V.



Bronze Sponsors

B-MS/Pfizer B.V.



Ervaring samenbrengen om mogelijkheden te vergroten

Cook Medical



NODIA



Optimed



Pfizer



Thrombosis and Haemostasis

**Thrombosis
and** International Journal
for Vascular Biology and Medicine
Haemostasis

Roche Diagnostics Nederland B.V.



Siemens Healthcare Diagnostics B.V.

SIEMENS

Stago BNL



Werfen B.V.

